Cafepharma Today

June 18 2025 - US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
Xaira releases 8-million-cell map of gene functions to fuel AI drug discovery
AbbVie’s migraine drug meets main goal in head-to-head study with topiramate
FDA launches new priority review voucher program for biopharmas that ‘align with national priorities’
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Alnylam announces publication of pre-clinical results with ALN-AS1
The Fly on the Wall
Wednesday, May 21, 2014 - 11:23am
tags:
Alnylam, ALN-AS1, hepatic porphyrias
Stryker must face class action employment claims
Mass Device
Wednesday, May 21, 2014 - 11:20am
tags:
devices, employment litigation, Stryker
3 Key Takeaways From Medtronic’s Earnings
Motley Fool
Wednesday, May 21, 2014 - 11:18am
tags:
Medtronic, earnings, devices
Merck says Zontivity approved for reduction of thrombotic cardiovascular events
The Fly on the Wall
Wednesday, May 21, 2014 - 11:16am
tags:
Merck, thrombotic cardiovascular events, Zontivity, FDA
Takeda’s Bowel Disease Drug Approved by U.S. Regulators
Bloomberg
Wednesday, May 21, 2014 - 10:26am
tags:
Takeda, FDA, Entyvio, vedolizumab, ulcerative colitis, Crohn's Disease
Valeant’s Pursuit of Allergan: Go Big or Go Home
Motley Fool
Wednesday, May 21, 2014 - 10:18am
tags:
Allergan, Valeant Pharmaceuticals, M&A
Vertex: A Company-Defining Event Offers A Buying Opportunity
Seeking Alpha
Wednesday, May 21, 2014 - 10:16am
tags:
Vertex Pharmaceuticals, Kalydeco
Baxter provides U.S. regulatory update on HyQvia
The Fly on the Wall
Wednesday, May 21, 2014 - 10:13am
tags:
Baxter International, HyQvia, primary immunodeficiency, Halozyme
A New Kind of Free Speech: Drug Reps' Pitches to Doctors
The New Yorker
Wednesday, May 21, 2014 - 10:08am
tags:
free speech, off-label, physicians, drug reps
AstraZeneca Gets Woodford Backing of Pfizer Bid Rejection
Bloomberg
Wednesday, May 21, 2014 - 9:02am
tags:
Pfizer, M&A, AstraZeneca
Can AstraZeneca Live Up To CEO's Growth Plans? A Look At Its Pipeline
Forbes
Wednesday, May 21, 2014 - 8:52am
tags:
AstraZeneca, Pascal Soriot, pipeline
The Biggest Biotech Wins of the Week
Motley Fool
Wednesday, May 21, 2014 - 8:50am
tags:
Halozyme, Eli Lilly, Isis Pharmaceuticals
[video] Could Pfizer Turn Hostile Towards AstraZeneca?
Bloomberg
Wednesday, May 21, 2014 - 8:27am
tags:
Pfizer, AstraZeneca, M&A
Takeda Denies Hiding Diabetes Drug Risks in Nevada Trial
Bloomberg
Tuesday, May 20, 2014 - 5:38pm
tags:
Takeda, diabetes, Actos, bladder cancer
Sun Pharma response to import ban inadequate - FDA
Yahoo/Reuters
Tuesday, May 20, 2014 - 4:20pm
tags:
Sun Pharma, India, FDA, drug importation
AstraZeneca says 'absolutely clear' that Pfizer offer final, can't be raised
The Fly on the Wall
Tuesday, May 20, 2014 - 4:05pm
tags:
AstraZeneca, Pfizer, M&A
SEC cries insider trading in GTx's halted cancer trial
Fierce Pharma
Tuesday, May 20, 2014 - 4:04pm
tags:
SEC, GTx, Capesaris
Side effect analysis suggests Gilead's hep C wonder Sovaldi is safer than rivals, too
Fierce Pharma
Tuesday, May 20, 2014 - 11:46am
tags:
Sovaldi, side effects, hepatitis C, Gilead Sciences
AstraZeneca Rebuffs Pfizer's "Final" Offer; Now What?
Motley Fool
Tuesday, May 20, 2014 - 11:44am
tags:
AstraZeneca, Pfizer, M&A
Ophthotech deal with Novartis leaves Fovista well-positioned, says Stifel
The Fly on the Wall
Tuesday, May 20, 2014 - 11:24am
tags:
Ophthotech, Fovista, Novartis, wet age-related macular degeneration, wet-AMD

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

AI Effects on Drug Patents
In the Pipeline
Mirror Morphine
In the Pipeline
Vaccine Advice, Vandalized
In the Pipeline
Novo Nordisk's Canadian Mistake
In the Pipeline
The Bethesda Declaration
In the Pipeline
Taurine and Aging: Is There Anything to It?
In the Pipeline
Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.